Canada Markets close in 2 hrs 54 mins
  • S&P/TSX

    17,251.12
    -145.44 (-0.84%)
     
  • S&P 500

    3,614.92
    -23.43 (-0.64%)
     
  • DOW

    29,596.37
    -314.00 (-1.05%)
     
  • CAD/USD

    0.7707
    +0.0008 (+0.11%)
     
  • CRUDE OIL

    44.87
    -0.66 (-1.45%)
     
  • BTC-CAD

    25,182.89
    +1,356.20 (+5.69%)
     
  • CMC Crypto 200

    381.55
    +16.95 (+4.65%)
     
  • GOLD FUTURES

    1,781.10
    -7.00 (-0.39%)
     
  • RUSSELL 2000

    1,824.02
    -31.25 (-1.68%)
     
  • 10-Yr Bond

    0.8460
    +0.0040 (+0.48%)
     
  • NASDAQ

    12,156.26
    -49.59 (-0.41%)
     
  • VOLATILITY

    21.27
    +0.43 (+2.06%)
     
  • FTSE

    6,266.19
    -101.39 (-1.59%)
     
  • NIKKEI 225

    26,433.62
    -211.09 (-0.79%)
     
  • CAD/EUR

    0.6444
    +0.0013 (+0.20%)
     

Is Replimune Group, Inc. (NASDAQ:REPL) Popular Amongst Insiders?

Simply Wall St
·5 min read

The big shareholder groups in Replimune Group, Inc. (NASDAQ:REPL) have power over the company. Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable percentage of the smaller ones. I generally like to see some degree of insider ownership, even if only a little. As Nassim Nicholas Taleb said, 'Don’t tell me what you think, tell me what you have in your portfolio.

Replimune Group has a market capitalization of US$1.9b, so we would expect some institutional investors to have noticed the stock. Our analysis of the ownership of the company, below, shows that institutions own shares in the company. Let's delve deeper into each type of owner, to discover more about Replimune Group.

Check out our latest analysis for Replimune Group

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About Replimune Group?

Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.

As you can see, institutional investors have a fair amount of stake in Replimune Group. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Replimune Group, (below). Of course, keep in mind that there are other factors to consider, too.

earnings-and-revenue-growth
earnings-and-revenue-growth

It would appear that 12% of Replimune Group shares are controlled by hedge funds. That catches my attention because hedge funds sometimes try to influence management, or bring about changes that will create near term value for shareholders. Our data shows that Omega Fund Management, LLC is the largest shareholder with 12% of shares outstanding. For context, the second largest shareholder holds about 11% of the shares outstanding, followed by an ownership of 8.1% by the third-largest shareholder. Furthermore, CEO Philip Astley-Sparke is the owner of 3.0% of the company's shares.

We also observed that the top 7 shareholders account for more than half of the share register, with a few smaller shareholders to balance the interests of the larger ones to a certain extent.

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too.

Insider Ownership Of Replimune Group

While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.

Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.

It seems insiders own a significant proportion of Replimune Group, Inc.. Insiders own US$195m worth of shares in the US$1.9b company. That's quite meaningful. Most would say this shows a good degree of alignment with shareholders, especially in a company of this size. You can click here to see if those insiders have been buying or selling.

General Public Ownership

The general public, with a 13% stake in the company, will not easily be ignored. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.

Private Equity Ownership

With an ownership of 31%, private equity firms are in a position to play a role in shaping corporate strategy with a focus on value creation. Some might like this, because private equity are sometimes activists who hold management accountable. But other times, private equity is selling out, having taking the company public.

Next Steps:

I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. For example, we've discovered 3 warning signs for Replimune Group that you should be aware of before investing here.

But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.